Cell-Penetrating NF-κB Inhibitor Peptide Reduces Diabetic Kidney Damage by 40%
A cell-permeable NEMO-binding domain peptide reduced albuminuria by over 40% and improved kidney pathology in a type 2 diabetic mouse model by blocking NF-κB inflammatory signaling.
Quick Facts
What This Study Found
Active NBD peptide reduced albuminuria by >40%, decreased podocyte loss and basement membrane thickness, and modulated inflammatory markers in a type 2 diabetic nephropathy mouse model.
Key Numbers
>40% average reduction in albuminuria; doses of 10 and 6 mcg/g body weight; first nephroprotective NBD study in T2D model
How They Did This
Animal study using obese diabetic mice randomized to active NBD peptide (two doses), inactive mutant peptide, or vehicle, with in-vivo imaging, kidney histology, and in-vitro mesangial cell NF-κB assays.
Why This Research Matters
Diabetic kidney disease is the leading cause of kidney failure worldwide. A peptide that blocks the central inflammatory pathway driving kidney damage could offer a targeted therapy beyond blood sugar control.
The Bigger Picture
This demonstrates that cell-penetrating peptides can deliver anti-inflammatory payloads directly to diseased kidneys, opening a new therapeutic approach for diabetic nephropathy.
What This Study Doesn't Tell Us
Mouse model; sample size not clearly specified; preliminary evidence; peptide stability and delivery optimization needed for clinical translation; long-term effects not assessed.
Questions This Raises
- ?Can NBD peptide be formulated for clinical delivery to human kidneys?
- ?Would combining NBD peptide with standard diabetic kidney disease treatments provide additive benefit?
- ?How does the peptide achieve selective renal accumulation?
Trust & Context
- Key Stat:
- >40% albuminuria reduction Active NBD peptide significantly improved kidney damage markers in type 2 diabetic mice
- Evidence Grade:
- Preliminary animal study with promising results including kidney-selective delivery and dose-response data, but limited by unspecified sample sizes and single disease model.
- Study Age:
- Published in 2020; NF-κB-targeted peptide therapies for diabetic nephropathy remain in preclinical development.
- Original Title:
- Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy.
- Published In:
- International journal of molecular sciences, 21(12) (2020)
- Authors:
- Opazo-Ríos, Lucas, Plaza, Anita, Sánchez Matus, Yenniffer, Bernal, Susana, Lopez-Sanz, Laura, Jimenez-Castilla, Luna, Carpio, Daniel, Droguett, Alejandra, Mezzano, Sergio, Egido, Jesús, Gomez-Guerrero, Carmen
- Database ID:
- RPEP-05043
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Can peptides treat diabetic kidney disease?
A cell-penetrating peptide that blocks NF-κB inflammatory signaling reduced kidney damage markers by over 40% in diabetic mice, showing promise for targeted peptide therapy.
What is NF-κB and why target it in kidney disease?
NF-κB is a master inflammatory switch that links high blood sugar to kidney damage in diabetes. Blocking it with a targeted peptide reduces the inflammation driving kidney disease progression.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05043APA
Opazo-Ríos, Lucas; Plaza, Anita; Sánchez Matus, Yenniffer; Bernal, Susana; Lopez-Sanz, Laura; Jimenez-Castilla, Luna; Carpio, Daniel; Droguett, Alejandra; Mezzano, Sergio; Egido, Jesús; Gomez-Guerrero, Carmen. (2020). Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy.. International journal of molecular sciences, 21(12). https://doi.org/10.3390/ijms21124225
MLA
Opazo-Ríos, Lucas, et al. "Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Peptide Improves Albuminuria and Renal Lesions in an Experimental Model of Type 2 Diabetic Nephropathy.." International journal of molecular sciences, 2020. https://doi.org/10.3390/ijms21124225
RethinkPeptides
RethinkPeptides Research Database. "Targeting NF-κB by the Cell-Permeable NEMO-Binding Domain Pe..." RPEP-05043. Retrieved from https://rethinkpeptides.com/research/opazo-rios-2020-targeting-nfb-by-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.